BofA update shows where active managers are putting money
LONDON - Verici Dx plc (AIM:VRCI), a developer of advanced clinical diagnostics for organ transplant, announced Tuesday that shareholders approved all resolutions at its Annual General Meeting (AGM).
According to a company statement, the five resolutions presented at the meeting received overwhelming support, with approval rates ranging from 99.85% to 100%.
Resolution 2 received the lowest approval rate at 99.85%, with 718,633 votes against, while Resolution 4 achieved the highest support with virtually 100% approval and only 21,408 votes against.
The first resolution passed with 99.98% support, representing 469,065,903 votes in favor and 88,290 votes against. Resolution 3 also received 99.98% approval, while Resolution 5 passed with 99.96% of votes.
Verici Dx, which trades on London’s AIM market, focuses on developing diagnostic tools for organ transplantation. The specific details of the resolutions were not disclosed in the press release statement.
The meeting was held on July 29, 2025, as indicated in the company announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.